CEPI-U.S. for CEPI-U.S.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 9, 2020 | $7,000 | Replaced |
| 2nd Quarter - Amendment | Jul 29, 2022 | $40,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Request for Member support of appropriations from USAID to CEPI. Also seeking support for CEPI's COVID-19 vaccine work in the supplemental bills. In addition, seeking support for a bill that will update Neglected Tropical Disease Priority Review Vouchers at FDA. HR4553, Introduced this quarter, seeks to include MERS, Nipah, and Rift Valley Fever. Also support for language to be included in either stand alone or larger bill that would provide authority to contribute language to USAID to contribute to CEPI. Finally, Unsolicited Proposal Concept Note submitted to USAID for possible cooperative agreement funding relationship.
Foreign entity interest: Government of Norway in appropriations for CEPI
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JONES HATCHETT | Acting Director of BARDA at HHS 2016 |
| DAWN MYERS O'CONNELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.